Hepatitis c virus inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function o...

Full description

Saved in:
Bibliographic Details
Main Authors O'BOYLE, DONALD R. II, TU, YONG, KADOW, JOHN F, WANG, ALAN XIANGDONG, LEMM, JULIE A, FRIDELL, ROBERT A, BELEMA, MAKONEN, KUMAR, INDASI GOPI, MEANWELL, NICHOLAS A, GUPTA, SAMAYAMUNTHULA VENKATA SATYA ARUN KUMAR, GAO, MIN, WANG, CHUN-FU, LOPEZ, OMAR D, SUN, JIN-HUA, HEWAWASAM, PIYASENA, SRINIVASU, POTHUKANURI, WANG, YING-KAI, XU, NING-NING, KUMAR, PONUGUPATI SURESH
Format Patent
LanguageChinese
English
Published 01.03.2014
Subjects
ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
Bibliography:Application Number: TW20132101215